FDA approves immune checkpoint inhibitor drug for patients with resectable locally advanced head and neck cancer, backed by Dana-Farber research
June 13, 2025
June 13, 2025
BOSTON, Massachusetts, June 13 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
FDA approves immune checkpoint inhibitor drug for patients with resectable locally advanced head and neck cancer, backed by Dana-Farber research
*
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally adv . . .
* * *
FDA approves immune checkpoint inhibitor drug for patients with resectable locally advanced head and neck cancer, backed by Dana-Farber research
*
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally adv . . .